证券代码：603014 证券简称：威高血净 公告编号：2025-009 山东威高血液净化制品股份有限公司 关于变更公司注册资本、公司类型、修订公司章程 并办理工商变更的公告 山东威高血液净化制品股份有限公司（以下简称"公司"、"本公司"）于2025年7 月21日召开第二届董事会第十二次会议，审议通过了《关于变更公司注册资本、公 司类型、修订<公司章程>并办理工商变更的议案》。此次章程修订事项已获公司2023 年第一次临时股东大会授权，该议案无需提交股东大会审议，具体情况如下： 一、公司注册资本、公司类型变动情况 根据中国证券监督管理委员会出具的《关于同意山东威高血液净化制品股份有 限公司首次公开发行股票注册的批复》（证监许可〔2025〕526 号），并经上海证券交 易所同意，公司首次公开发行人民币普通股（A 股）股票（以下简称"本次发行"） 4,113.9407 万股，并于 2025 年 5 月 19 日在上海证券交易所主板上市。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据安永华明会计师事务所（特殊普通 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-011 山东威高血液净化制品股份有限公司 监事会认为：公司使用自筹资金支付募投项目部分款项并后续以募集资金等额 置换的事项，不存在损害公司及股东利益的情形，不会对募投项目的实施产生实质 性的影响，且履行的审议程序符合相关法律法规的规定，符合《上市公司募集资金 监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律法 规、规范性文件及公司募集资金管理制度相关规定，内容及程序合法合规。 综上所述，公司监事会同意公司使用自筹资金支付募投项目部分款项并后续以 募集资金等额置换。 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司关于使用自筹资金支付募 投项目部分款项后续以募集资金等额置换的公告》。 表决结果：3 票同意，0 票弃权，0 票反对。 特此公告。 审议通过了《关于使用自筹资金支付募投项目部分款项后续以募集资金等额置 换的议案》 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 重大遗漏， ...

证券代码：603014 证券简称：威高血净 公告编号：2025-010 山东威高血液净化制品股份有限公司 第二届董事会第十二次会议决议公告 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于使用自筹资金支付募投项目部分款项后续以募集资金 等额置换的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司关于使用自筹资金支付募 投项目部分款项后续以募集资金等额置换的公告》。 表决结果：9 票同意，0 票弃权，0 票反对。 （二）审议通过了《关于变更公司注册资本、公司类型、修订<公司章程>并办 理工商变更的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司关于变更公司注册资本、 公司类型、修订<公司章程>并办理工商变更的公告》。 表决结果：9 票同意，0 票弃权，0 票反对。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性 ...

Summary of Key Points Core Viewpoint The Chinese IPO market is showing signs of recovery in the first half of 2025, with a total of 94 new listings in A-shares and Hong Kong stocks, indicating a positive trend in capital market expansion, particularly for companies from Shandong province. Group 1: IPO Market Overview - As of June 2025, a total of 94 new companies were listed in A-shares and Hong Kong stocks, with A-shares contributing 51 new listings and raising 37.355 billion yuan, representing a year-on-year increase of approximately 16% in the number of new stocks and 15% in total financing compared to 2024 [1] - Shandong province contributed three new listings: Weigao Blood Purification (603014.SH), Xinhenghui (301678.SZ) in A-shares, and Nanshan Aluminum International (02610.HK) in Hong Kong [1] Group 2: Weigao Blood Purification - Weigao Blood Purification officially listed on the Shanghai Stock Exchange on May 19, 2025, with an issue price of 26.5 yuan per share, raising 1.09 billion yuan [2] - The stock price closed at 41.41 yuan per share on the first day, a 56.26% increase from the issue price, with a market capitalization reaching 17.036 billion yuan [2] - The company is a leader in the blood purification sector, focusing on the development, production, and sales of medical products, and has established a strong technological barrier with 257 domestic patents [2][3] Group 3: Xinhenghui Electronics - Xinhenghui Electronics was listed on the ChiNext board on June 20, 2025, with an issue price of 12.80 yuan per share, successfully raising 767 million yuan [5] - The company is a leader in smart card packaging materials, with a global market share of 30%, ranking second worldwide [5][6] - From 2021 to 2023, Xinhenghui's revenue grew from 548 million yuan to 767 million yuan, with a compound annual growth rate of 18.28% [6] Group 4: Nanshan Aluminum International - Nanshan Aluminum International, the only Shandong company listed in Hong Kong, focuses on high-end aluminum supply chain and has become the first aluminum company listed in Southeast Asia [9] - The company opened at 26.60 HKD but closed at 25.25 HKD on the first day, a decrease of 5.08%, although the stock price increased by 28.57% by the end of June [9][10] - From 2021 to 2023, Nanshan's revenue surged from 173 million USD to 678 million USD, with a net profit increase from 39.71 million USD to 174 million USD [10] Group 5: Other Companies and Trends - Several other Shandong companies are planning to list in Hong Kong, including Goer Microelectronics and Tianyue Advanced, indicating a trend of Shandong enterprises expanding into international markets [10][11] - The capital market in Shandong is experiencing both new listings and some companies opting for voluntary delisting, such as Yulong Gold [13][14] - The overall landscape of Shandong's capital market is characterized by a mix of growth and restructuring, with a focus on high-end manufacturing and technology sectors [15]

Core Viewpoint - Weigao Blood Purification's stock closed at 37.69 yuan, down 1.10%, with a rolling PE ratio of 33.88 times and a total market value of 15.505 billion yuan [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company ranks fifth in the domestic market for peritoneal dialysis solutions with a market share of 3.6% [1] Financial Performance - In Q1 2025, the company reported revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% [2] - The gross profit margin for the company stands at 40.92% [2] Market Position - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, positioning Weigao Blood Purification at 71st in the industry [1][2] - The company has a total of 59,754 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ·本期赎回金额：35,000 万元。 ·赎回理财产品名称：结构性存款。 ·履行的审议程序：山东威高血液净化制品股份有限公司（以下简称"威高血 净"或"公司"）于 2025 年 5 月 27 日召开了第二届董事会第十一次会议和第二届监 事会第八次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司（含子公司，下同）在确保不影响募集资金项目建设和募集资金使用 的情况下，使用最高不超过人民币 74,000 万元（含本数）的暂时闲置募集资金进行 现金管理，增加公司收益，为公司及股东获取投资回报。 一、本次现金管理到期赎回情况 证券代码：603014 证券简称：威高血净 公告编号：2025-007 山东威高血液净化制品股份有限公司董事会 2025 年 7 月 2 日 单位：万元 序号 购买主体 产品类型 到期时间 实际投资金额 实际收回本金 实际收 ...

Core Insights - The company, Weigao Blood Purification, closed at 36.39 yuan on June 24, with a 1.45% increase, resulting in a rolling PE ratio of 32.72 times and a total market capitalization of 14.971 billion yuan [1][2] - The average PE ratio in the medical device industry is 49.12 times, with a median of 36.07 times, placing Weigao Blood Purification at the 71st position in the industry ranking [1][2] - As of May 19, 2025, the number of shareholders increased to 59,754, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis fluid [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company also ranks fifth in the domestic market for peritoneal dialysis fluid with a market share of 3.6% for the Weigao Tailmao brand [1] Financial Performance - In the first quarter of 2025, the company reported a revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% year-on-year [2] - The gross profit margin for the company stands at 40.92% [2]

Core Viewpoint - Weigao Blood Purification, as the first leading enterprise in the blood purification sector to be listed on the A-share market, is seen as a bellwether for industry development, focusing on "long-termism" and innovation-driven growth since its listing on May 19 [1] Group 1: Company Strategy - The company emphasizes the importance of product development and technological innovation, committing to continuous R&D investment to maintain its technological edge [2] - Weigao Blood Purification is advancing its fundraising projects, planning to invest in intelligent production for blood purification and the development of new consumables and equipment [2] Group 2: R&D Investment - R&D has been a key focus for Weigao Blood Purification, with significant efforts in core products like blood dialysis machines and peritoneal dialysis solutions [3] - The company has consistently invested over 100 million annually in R&D, with planned investments of 183 million, 155 million, and 165 million yuan from 2022 to 2024, respectively [3] Group 3: Industry Positioning - Weigao Blood Purification has established a comprehensive industry chain covering key areas of blood purification, with products available in over 6,000 medical institutions nationwide [4] - The company’s innovative products, such as the first domestic neutral peritoneal dialysis solution, enhance patient quality of life and set benchmarks for product innovation in the industry [4] - Collaborations with companies like Nikkiso to introduce advanced technologies and localize improvements are driving technological upgrades in domestic blood purification equipment [4] Group 4: Future Outlook - The company is expected to continue leveraging innovation to create industrial value and lead industry development, with ongoing R&D outputs and the implementation of fundraising projects [4]

华泰联合证券有限责任公司关于 山东威高血液净化制品股份有限公司 三、培训成果 通过此次培训，威高血净董事、监事、高级管理人员等相关人员加深了对中 国证券监督管理委员会和上海证券交易所关于上市公司规范运作的了解和认识， 了解了违法违规行为的危害性，促使上述对象增强法制观念和诚信意识，加强理 解作为上市公司管理人员在公司规范运作方面所应承担的责任和义务。此次培训 有助于上市公司深刻认识到规范运作的重要性和违法违规的危害性，进而促使上 市公司进一步完善治理机制、规范内控制度，进一步提升威高血净的规范运作水 平。 (本页无正文,为《华泰联合证券有限责任公司关于山东威高血液净化制品股份 有限公司 2025 年度持续督导培训情况报告》之签章页) 2025 年度持续督导培训情况报告 上海证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》等有关规定以及威高血净的实际情况，对威高血净的董事、 监事、高级管理人员等相关人员进行了 202 ...

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]